Levosimendan improves exercise performance in patients with advanced chronic heart failure

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Cardiopulmonary exercise testing (CPET) parameters like peak VO2 and VE/VCO2 slope are crucial prognostic indicators in advanced chronic heart failure (ADHF).
• The inodilator levosimendan's effect on CPET parameters in stable ADHF patients requires further investigation.

Purpose of the Study:

• To evaluate the impact of levosimendan on CPET parameters in patients with stable ADHF.
• To assess changes in peak VO2, VE/VCO2 slope, and B-type natriuretic peptide (BNP) levels following levosimendan administration.

Main Methods:

• A double-blind, placebo-controlled study involving 42 ADHF patients (peak VO2 < 12 mL/min/kg).
• Patients received either intravenous levosimendan (n=23) or placebo (n=19).
• CPET, spirometry, alveolar capillary gas diffusion, New York Heart Association class, and BNP levels were measured before and 24 hours after infusion.

Main Results:

• Levosimendan significantly increased peak VO2 (9.8 to 11.0 mL/kg/min, P<0.005) and decreased VE/VCO2 slope (41.9 to 36.6, P<0.001).
• BNP levels significantly decreased with levosimendan (1163 to 509 pg/mL, P<0.001), while no significant changes were observed in placebo group.
• No significant changes were noted in haemoglobin, creatinine, blood urea nitrogen, or alveolar capillary gas diffusion.

Conclusions:

• Levosimendan treatment significantly improves peak VO2 and reduces VE/VCO2 slope in ADHF patients.
• Levosimendan also effectively reduces BNP levels, indicating a potential benefit in managing ADHF.
• These findings suggest levosimendan is a valuable therapeutic option for improving exercise capacity and prognostic markers in ADHF.